Liaoning University of Traditional Chinese Medicine

About: Liaoning University of Traditional Chinese Medicine is a education organization based out in Shenyang, China. It is known for research contribution in the topics: Randomized controlled trial & Acupuncture. The organization has 2040 authors who have published 1326 publications receiving 14664 citations.

[Adjunctive therapy of xuezhikang capsule for coronary heart disease: a systematic review and meta-analysis of randomized controlled trials].

Abstract: Objective To systematically evaluate the effect and safety of Xuezhikang Capsule (XZKC) for adjuvant treatment for coronary heart disease (CHD) patients accompanied with or without dyslipidemia Methods China National Knowledge Infrastructure (CNKI) Database, Chongqing VIP Database (VIP), Wanfang Data base, Cochrane Library, and Medline (PubMed) were retrieved with the deadline of August 30, 2013 Randomized controlled trials (RCT) of XZKC in treating CHD patients with or without dyslipidemia were all included Assessment of bias risk for included studies was conducted according to the Cochrane Handbook for Systematic Reviews of Intervention (Version 502): Criteria for judging risk of bias in the "risk of bias" assessment tool Review Management (510) was employed for data statistics If there was no significant heterogeneity, results from the random-effect model were presented If the heterogeneity was not substantial, a meta-analysis was not performed and a narrative and qualitative summary was performed instead Results A total of 28 RCTs (6,949 patients) were included after screening results The methodological quality of included trial was generally lower Results of Metaanalysis showed that XZKC was beneficial for CHD patients in decreasing cardiovascular events: when compared with the basic treatment group, the relative risk (RR) was 053 and 95% confidence interval (CI) was [035, 081]; when compared with the placebo + basic treatment group, RR was 052 and 95% CI was [042, 065]; when compared with the basic treatment group, RR for improving symptoms of angina was 120 and 95% CI was [1 12, 130]; when compared with the basic treatment group, RR for improving abnormal ECG was 138 and 95% CI was [121, 157] Thirteen studies showed that XZKC + basic treatment was obviously superior in lowering total cholesterol (TC) to that of the basic treatment group Three studies showed that XZKC + basic treatment was obviously superior in lowering total cholesterol (TC) to that of the placebo + basic treatment group Thirteen studies showed that XZKC + basic treatment was obviously superior in lowering low density lipoprotein cholesterol (LDL-C) to that of the basic treatment group Three studies showed that XZKC + basic treatment was obviously superior in lowering LDL-C to that of the placebo + basic treatment group A total of 18 studies describing adverse reactions (ADs) involved 61 ADs in the XZKC + basic treatment group All suffered from mild symptoms or were improved after treatment No severe ADs occurred Conclusion Treatment of CHD by XZKC might lower the occurrence of cardiovascular events in CHD patients accompanied with or without dyslipidemia, relieve clinical symptoms, improve ECG, lower blood lipid levels, and with less adverse reactions

Anti-Tumor Effective Fractions of Fuling

Abstract: Objective: To study the anti-proliferation effect on SGC-7901 cell and Bcap-37 cell of Fuling extracts. Methods: The proliferating inhibition of the five Fuling extracts including petroleum ether fraction,EtOAc fraction,polysaccharides,alcohol eluated fraction( AEF) and water eluated fraction( WEF) from macroporous absorption resin against SGC-7901 cell and Bcap-37 cell was assessed by MTT assays and seropharmacology method. Results: The IC50of polysaccharides on Bcap-37 cell was 29. 29 μg /mL,that of EtOAc was 57. 84 μg /mL. The OD values of Polysaccharides and EtOAc fraction were decreased compared with those of the control group( P 0. 01),and there was no difference between the fractions and positive group( P 0.05) in the experiment of seropharmacology. The IC50on SGC-7901 of polysaccharides and EtOAc fraction was respectively 25.38 μg /mL and 56. 27 μg /mL. The OD values of Polysaccharides and EtOAc fraction were decreased compared with those of the control group( P 0. 01),and there was no difference between the fractions and positive group( P 0. 05) in the experiment of seropharmacology. Conclusion: The effective fractions of Fuling against Bcap-37 cell and SGC-7901 cell are polysaccharides and EtOAc fraction in a time and dose dependent manner,which provides evidence for the further study on anticancer activity of Fuling.

The complete chloroplast genome of Ligusticum jeholense (Umbelliferae, Ligusticum L.).

Abstract: Ligusticum jeholense is an important medicinal plant. Chloroplast genome information is helpful for the development of molecular markers and the study of plant phylogeny. In this study, we report the complete chloroplast genome sequence of L. jeholense. The genome sequence is 148,493 bp in size (GenBank accession number MN652885), with 37.25% GC contents. There are 127 genes in the genome, including 83 known protein-coding genes (PCGs), 36 transfer RNAs (tRNAs), and 8 ribosomal RNAs (rRNAs). The maximum-likelihood method are used to construct phylogenetic tree of 32 species. These data will provide certain theoretical basis for plant genetics research.

Defining matrix Gla protein expression in the Dunkin-Hartley guinea pig model of spontaneous osteoarthritis.

Abstract: Matrix Gla (γ-carboxyglutamate) protein (MGP) is considered a strong inhibitor of ectopic calcification, and it has been associated with OA severity, although not conclusively. We utilized male Dunkin-Hartley (DH) guinea pigs to investigate the expression of MGP throughout aging and disease pathogenesis in a spontaneous model. Twenty-five male DH guinea pigs were obtained and nurtured to several timepoints, and then randomly and equally divided by age into five subgroups (1-, 3-, 6-, 9-, and 12-months, with the 1-month group as the reference group). DH guinea pigs in each group were euthanized at the designated month-age and the left or right medial tibial plateaus cartilages were randomly excised. OA severity was described by modified Mankin Score (MMS) at microscopy (Safranin O/Fast Green stain). Proteomic evaluation using isobaric tags for relative and absolute quantification (iTRAQ) was performed to validate the age-related changes in the MGP profiles, and immunohistochemistry (IHC) methods were applied for semi-quantitative determination of MGP expression in articular cartilage. The histopathologic findings validated the increasing severity of cartilage degeneration with age in the DH guinea pigs. The MMS showed significant, stepwise (every adjacent comparison P < 0.05) disease progression with month-age. The iTRAQ indicated that MGP levels increased significantly with advancing age (P < 0.05), as supported by the IHC result (P < 0.05). Increased expression of MGP in male DH guinea pigs was present throughout aging and disease progression and may be link to increased OA severity. Further studies are needed to investigate and confirm the association between MGP levels and OA severity.

Simultaneous Determination of Escin Ia and Its Isomer Isoescin Ia by LC–MS–MS: Application to a Pharmacokinetic Study of Escin Ia in Rats

Abstract: A rapid and sensitive LC–MS–MS method for the simultaneous determination of escin Ia and isoescin Ia in rat plasma, urine, feces and bile samples was developed and validated. Analytes and telmisartan [internal standard (IS)] were extracted by solid-phase extraction on C18 cartridges. Components in the extract were separated on an HC-C18 column (5 μm, 150 × 4.6 mm i.d.) using 10 mM ammonium acetate–methanol–acetonitrile (40:30:30, v/v/v) as the mobile phase. The method demonstrated good linearity from 5 ng mL−1 (LLOQ) to 1,500 ng mL−1 for both escin Ia and isoescin Ia. Intra- and inter-day precision measured as RSD was within ±15%. Recoveries and matrix effects of both escin Ia and isoescin Ia were satisfactory in all four matrices examined. The method was successfully applied to a pharmacokinetic study in Wistar rats after a single intravenous administration of escin Ia at the dose of 1.0 mg kg−1.